Current approaches to visceral leishmaniasis treatment in solid organ transplant recipients

References

• WHO. Control of the leishmaniasis: report of a meeting of the WHO Expert Committee on the Control of Leishmaniases. Geneva: World Health Organization; 2010. http://apps.who.int/iris/handle/10665/44412
   Google Scholar
• Kevric I, Ma C, Jh K. New world and old world leishmania infections: a practical review. Dermatol Clin. 2015;33:579–593.
   PubMed Web of Science ®Google Scholar
• de Vries HJ, Reedijk SH, Schallig HD. Cutaneous leishmaniasis: recent developments in diagnosis and management. Am J Clin Dermatol. 2015;16:99–109.
   PubMed Web of Science ®Google Scholar
• Antinori S, Cascio A, Parravicini C, et al. Leishmaniasis among organ transplant recipients. Lancet Infect Dis. 2008;8(3):191–199.
   PubMed Web of Science ®Google Scholar
• Schwartz BS, Mawhorter SD. Parasitic infections in solid organ transplantation. Am J Transplant. 2013;13:280–303.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Carrillo E, Lopez-Velez R, et al. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect. 2014;20:286–299.
   PubMed Web of Science ®Google Scholar
• Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the infectious diseases society of America (IDSA) and the American society of tropical medicine and hygiene (ASTMH). Am J Trop Med Hyg. 2017;96(1):24–45.
   PubMed Web of Science ®Google Scholar
• Clemente WT, Mourão PHO, Lopez-Medrano F, et al. Visceral and cutaneous leishmaniasis recommendations for solid organ recipients and donors. Transplantation. 2018 Feb;102(2S Suppl 2):S8–S15.
   PubMedGoogle Scholar
• Clemente W, Vidal E, Girao E, et al. Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study. Clin Microbiol Infect. 2015;21(1):89–95.
   PubMed Web of Science ®Google Scholar
• Clemente WT, Rabello A, Faria LC, et al. High prevalence of asymptomatic leishmania spp infection among liver transplant recipients and donors from an endemic area of Brazil. Am J Transplant.. 2014;14(1):96–101.
   PubMed Web of Science ®Google Scholar
• No JH. Visceral leishmaniasis: revisiting current treatments and approaches for future discoveries. Acta Trop. 2016;155:113–123.
   PubMed Web of Science ®Google Scholar
• Singh K, Garg G, Ali V. Current therapeutics, their problems and thiol metabolism as potential drug targets in leishmaniasis. Curr Drug Metab. 2016;17:897–919.
   PubMed Web of Science ®Google Scholar
• Kaur G, Rajput B. Comparative analysis of the omics technologies used to study antimonial, amphotericin B, and pentamidine resistance in leishmania. J Parasitol Res. 2014;2014. http:s//doi.org/10.1155/2014/726328
   Google Scholar
• Pagliano P, Esposito S. Visceral leishmaniosis in immunocompromised host: an update and literature review. J Chemother. 2017;29(5):261–266.
   PubMed Web of Science ®Google Scholar
• Akbari M, Oryan A, Hatam G. Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop. 2017;172:86–90.
   PubMed Web of Science ®Google Scholar
• Gajurel K, Dhakal R, Deresinski S. Leishmaniasis in solid organ and hematopoietic stem cell transplant recipients. Clin Transplant. 2017;31:e12867.
   Web of Science ®Google Scholar
• Kedzierski L, Sakthianandeswaren A, Curtis JM, et al. Leishmaniasis: current treatment and prospects for new drugs and vaccines. Curr Med Chem. 2009;16:599–614.
   PubMed Web of Science ®Google Scholar
• Mishra J, Saxena A, Singh S. Chemotherapy of leishmaniasis: past, present and future. Curr Med Chem. 2007;14(10):1153–1169.
   PubMed Web of Science ®Google Scholar
• Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, et al. Leishmaniasis: a review. F1000 Res. 2017;6:750.
   PubMedGoogle Scholar
• FDA. FDA briefing document for the anti-infective drugs advisory committee meeting. 2013 Oct 18.  Maryland: FDA.
   Google Scholar
• Dorlo TP, Balasegaram M, Beijnen JH, et al. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J Antimicrob Chemother. 2012;67:2576–2597.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral leishmaniasis. Ther Adv Infect Dis. 2016 Jun;3(3–4):98–109.
   PubMed Web of Science ®Google Scholar
• Asin MAPJ, Carrasco-Anton N, Fernandez-Ruiz M, et al. Experience with miltefosine for persistent or relapsing visceral leishmaniasis in solid organ transplant recipients: a case series from Spain. Transpl Infect Dis. 2017;19:e12623.
   Web of Science ®Google Scholar
• Copeland NK, Aronson NE. Leishmaniasis: treatment updates and clinical practice guidelines review. Curr Opin Infect Dis. 2015;28:426–437.
   PubMed Web of Science ®Google Scholar
• Ostyn B, Hasker E, Dorlo TP, et al. Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia. PLoS One. 2014;9:e100220.
   PubMed Web of Science ®Google Scholar
• Jhingran A, Chawla B, Saxena S, et al. Paromomycin: uptake and resistance in leishmania donovani. Mol Biochem Parasitol. 2009;164:111–117.
   PubMed Web of Science ®Google Scholar
• Bhandari V, Sundar S, Dujardin JC, et al. Elucidation of cellular mechanisms involved in experimental paromomycin resistance in leishmania donovani. Antimicrob Agents Chemother. 2014;58:2580–2585.
   PubMed Web of Science ®Google Scholar
• Gazanion E, Fernandez-Prada C, Papadopoulou B, et al. Cos-Seq for high-throughput identification of drug target and resistance mechanisms in the protozoan parasite leishmania. Proc Natl Acad Sci U S A. 2016;113:E3012–3021.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med. 2007 Jun 21;356(25):2571–2581.
   PubMed Web of Science ®Google Scholar
• Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial. J Assoc Physicians India. 1991 Apr;39(4):314–316.
   PubMedGoogle Scholar
• Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013 Jan;14(1):53–63.
   PubMed Web of Science ®Google Scholar
• van Griensven J, Balasegaram M, Meheus F, et al. Combination therapy for visceral leishmaniasis. Lancet Infect Dis. 2010 Mar;10(3):184–194.
   PubMed Web of Science ®Google Scholar
• Sundar S, Sinha PK, Verma DK, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2011;105:115–117.
   PubMed Web of Science ®Google Scholar
• Barragan P, Lopez-Velez R, Olmo M, et al. Visceral leishmaniasis treated with antimonials/paromomycin followed by itraconazole/miltefosine after standard therapy failures in a human immunodeficiency virus-infected patient. Am J Trop Med Hyg. 2010;83(1):10–12.
   PubMed Web of Science ®Google Scholar
• Laguna F, Lopez-Velez R, Soriano V, et al. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect. 1994;28:255–259.
   PubMed Web of Science ®Google Scholar
• Nyakundi PM, Gachihi GS, Muigai RK, et al. Relationship between direct agglutination test and splenic aspirate smear parasite load in visceral leishmaniasis at Baringo District, Kenya. East Afr Med J. 1994;71(9):598–600.
   PubMed Web of Science ®Google Scholar
• Ministério da Saúde do Brasil. Visceral leishmaniasis: clinical recommendations for lethality reduction. Brasil: Ministério da Saúde do Brasil; 2011. Available from: http://bvsms.saude.gov.br/bvs/publicacoes/leishmaniose_visceral_reducao_letalidade.pdf
   Google Scholar
• Schaefer KU, Schoone GJ, Gachihi GS, et al. Visceral leishmaniasis: use of the polymerase chain reaction in an epidemiological study in Baringo District, Kenya. Trans R Soc Trop Med Hyg. 1995;89:492–495.
   PubMed Web of Science ®Google Scholar
• Carrillo E, Carrasco-Anton N, Lopez-Medrano F, et al. Cytokine release assays as tests for exposure to leishmania, and for confirming cure from leishmaniasis, in solid organ transplant recipients. PLoS Negl Trop Dis. 2015;9:e0004179.
   PubMed Web of Science ®Google Scholar
• Balasegaram M, Ritmeijer K, Lima MA, et al. Liposomal amphotericin B as a treatment for human leishmaniasis. Expert Opin Emerg Drugs. 2012;17:493–510.
   PubMed Web of Science ®Google Scholar
• Ritter U, Frischknecht F, Van Zandbergen G. Are neutrophils important host cells for leishmania parasites? Trends Parasitol. 2009;25:505–510.
   PubMed Web of Science ®Google Scholar
• Taslimi Y, Zahedifard F, Rafati S. Leishmaniasis and various immunotherapeutic approaches. Parasitology. 2016;1–11.
   PubMed Web of Science ®Google Scholar
• Zulfiqar B, Shelper TB, Avery VM. Leishmaniasis drug discovery: recent progress and challenges in assay development. Drug Discov Today. 2017 Oct;22(10):1516–1531.
   PubMed Web of Science ®Google Scholar